Leps Christian, Bischoff Christian, Gockel Ines, Tegtbur Uwe, Kwast Stefan, Pökel Christoph, Voß Johannes, Rinser Hans-Jürgen, Falz Roberto, Busse Martin
Institute of Sports Medicine and Prevention, University Leipzig, Leipzig, Germany.
Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital Leipzig, Leipzig, Germany.
BMC Sports Sci Med Rehabil. 2025 Aug 9;17(1):232. doi: 10.1186/s13102-025-01275-3.
The current guidelines for physical activity often rely on self-reported data or short-term activity tracking. We aimed to explore device-based long-term physical activity tracking and its possible association with cancer survivors' cardiorespiratory fitness (CRF), metabolic health, and body composition.
In this observational analysis of a randomized controlled trial (CRBP-TS study), we reanalyzed data from 111 patients with breast, prostate, and colorectal cancer. Dependent variables included cardiorespiratory outcomes, body composition, metabolic biomarkers, and fatigue. A multiple linear regression model was used to analyze the data, considering age, gender, BMI, and baseline values. A consumer wearable device measured moderate-to-vigorous physical activity (MVPA) and steps continuously over six months, ensuring a detailed and accurate record of the participants' daily physical activity.
Physical activity data from all participants indicated a mean of moderate physical activity 108 min/wk (SD ± 88), vigorous physical activity 41 min/wk (SD ± 36), and 8498 steps/day (SD ± 2490). We observed that higher levels of MVPA were significantly associated with higher maximum oxygen uptake (VO; β = 0.5, 95% CI [0.02 to 1.0], p = 0.042), higher peak power output (PPO; β = 0.04, 95% CI [0.003 to 0.08], p = 0.037), and higher cardiac output (β = 0.6, 95% CI [0.2 to 1.1], p = 0.009). Additionally, more steps correlated significantly with higher VO (β = 0.27, 95% CI [0.04 to 0.51], p = 0.023), higher cardiac output (β = 0.2, 95% CI [0.013 to 0.47], p = 0.039), lower fat mass (β= -0.24, 95% CI [-0.44 to 0.03], p = 0.028), lower insulin (β=-4.2, 95% CI [-6.4 to -2.0], p < 0.000), and lower leptin (β=-0.56, 95% CI [-0.97 to -0.15], p = 0.008).
Continuous activity tracking with wearable devices provides an objective and standardized opportunity to investigate the amount of aerobic physical activity and its association with systemic health outcomes in cancer survivors. Our long-term activity data support a positive relationship between aerobic physical activity and cardiorespiratory fitness as well as metabolic health.
DRKS-ID: DRKS00020499; Registered 17 March 2020, https://drks.de/search/en/trial/DRKS00020499 .
当前的身体活动指南通常依赖自我报告数据或短期活动追踪。我们旨在探讨基于设备的长期身体活动追踪及其与癌症幸存者心肺适能（CRF）、代谢健康和身体成分之间的可能关联。
在这项对一项随机对照试验（CRBP - TS研究）的观察性分析中，我们重新分析了111例乳腺癌、前列腺癌和结直肠癌患者的数据。因变量包括心肺结局、身体成分、代谢生物标志物和疲劳。使用多元线性回归模型分析数据，同时考虑年龄、性别、体重指数（BMI）和基线值。一款消费级可穿戴设备连续六个月测量中度至剧烈身体活动（MVPA）和步数，确保详细、准确地记录参与者的日常身体活动。
所有参与者的身体活动数据显示，中度身体活动平均每周108分钟（标准差±88），剧烈身体活动平均每周41分钟（标准差±36），每天8498步（标准差±2490）。我们观察到，较高水平的MVPA与较高的最大摄氧量（VO；β = 0.5，95%置信区间[0.02至1.0]，p = 0.042）、较高的峰值功率输出（PPO；β = 0.04，95%置信区间[0.003至0.08]，p = 0.037）以及较高的心输出量（β = 0.6，95%置信区间[0.2至1.1]，p = 0.009）显著相关。此外，步数越多与较高的VO（β = 0.27，95%置信区间[0.04至0.51]，p = 0.023）、较高的心输出量（β = 0.2，95%置信区间[0.013至0.47]，p = 0.039）、较低的脂肪量（β = -0.24，95%置信区间[-0.44至0.03]，p = 0.028）、较低的胰岛素水平（β = -4.2，95%置信区间[-6.4至-2.0]，p < 0.000）以及较低的瘦素水平（β = -0.56，95%置信区间[-0.97至-0.15]，p = 0.008）显著相关。
使用可穿戴设备进行连续活动追踪为研究癌症幸存者的有氧身体活动量及其与全身健康结局的关联提供了一个客观、标准化的机会。我们的长期活动数据支持有氧身体活动与心肺适能以及代谢健康之间存在正相关关系。
DRKS编号：DRKS00020499；于2020年3月17日注册，https://drks.de/search/en/trial/DRKS00020499 。
